Oral Antivirals for High-risk COVID-19 Patients

Lauren Biehle, PharmD, BCPS, BCIDP; Jeremy W. Vandiver, PharmD, BCPS


US Pharmacist. 2022;47(7):34-41. 

In This Article


Despite limitations noted above, the development, authorization, and clinical availability of effective oral antivirals to prevent severe COVID-19 are important steps in combating this disease. There will be more research in the future to elucidate whether there is clinical benefit for N-R and molnupiravir in other situations (e.g., patients with acute infection without high-risk features, patients with long COVID-19 symptoms). Given that both molnupiravir and N-R have their own unique considerations, pharmacists will play an important role in patient selection, dosage adjustment, drug interaction management, dispensing, and patient counseling.